J
João Luiz Miraglia
Researcher at University of São Paulo
Publications - 33
Citations - 508
João Luiz Miraglia is an academic researcher from University of São Paulo. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 12, co-authored 24 publications receiving 337 citations. Previous affiliations of João Luiz Miraglia include Instituto Butantan & Federal University of São Paulo.
Papers
More filters
Journal ArticleDOI
Glucocorticoid: Major Factor for Reduced Immunogenicity of 2009 Influenza A (H1N1) Vaccine in Patients with Juvenile Autoimmune Rheumatic Disease
Nadia E. Aikawa,Lucia M.A. Campos,Clovis A. Silva,Jozélio Freire de Carvalho,Carla G. S. Saad,Guilherme Trudes,Alberto José da Silva Duarte,João Luiz Miraglia,Maria do Carmo Sampaio Tavares Timenetsky,Vilma dos Santos Trindade Viana,Ivan França,Eloisa Bonfa,Rosa Maria Rodrigues Pereira +12 more
TL;DR: This is the largest study to demonstrate a reduced but adequate immune response to H1N1 vaccine in patients with juvenile ARD and identified current glucocorticoid use as the major factor for decreased antibody production.
Journal ArticleDOI
High disease activity: an independent factor for reduced immunogenicity of the pandemic influenza a vaccine in patients with juvenile systemic lupus erythematosus.
Lucia M.A. Campos,Clovis A. Silva,Nadia E. Aikawa,Adriana Almeida de Jesus,Julio C. B. Moraes,João Luiz Miraglia,Maria A. Ishida,Cleonice Bueno,Rosa Maria Rodrigues Pereira,Eloisa Bonfa +9 more
TL;DR: The aim of this study was to assess the disease safety of and the possible influence of disease parameters and therapy on nonadjuvant influenza A H1N1 vaccine response of juvenile systemic lupus erythematosus (SLE) patients.
Journal ArticleDOI
Short-term effectiveness of COVID-19 vaccines in immunocompromised patients: A systematic literature review and meta-analysis
Alexandre R.MD MarraMS,Takaaki Kobayashi,Hiroyuki Suzuki,Mohammed Alsuhaibani,Bruna Marques Tofaneto,Luigi Makowski Bariani,Mariana de Amorim Auler,Jorge L. Salinas,Michael B. Edmond,Michelle Doll,Jose Mauro Kutner,João Renato Rebello Pinho,Luiz Vicente Rizzo,João Luiz Miraglia,Marin L. Schweizer +14 more
TL;DR: In this article , the short-term effectiveness of COVID-19 vaccines among immunocompromised patients to prevent laboratory-confirmed symptomatic CoV-19 infection was evaluated.
Journal ArticleDOI
Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial.
Esper G. Kallas,Alexander Roberto Precioso,Alexander Roberto Precioso,Ricardo Palacios,Beatriz Thomé,Patrícia Emília Braga,Tazio Vanni,Lucia M.A. Campos,Lilian Ferrari,Gabriela Mondini,Maria da Graça Salomão,Anderson da Silva,Heloisa Maxímo Espinola,Joane do Prado Santos,Cecília L. S. Santos,Maria do Carmo Sampaio Tavares Timenetsky,João Luiz Miraglia,Neuza Maria Frazatti Gallina,Daniela Weiskopf,Alessandro Sette,Raphaella Goulart,Rafael Tavares Salles,Alvino Maestri,Adriana M. E. Sallum,Sylvia Costa Lima Farhat,Neusa Keico Sakita,Juliana Carvalho Ferreira,Cassia G. T. Silveira,Priscilla R. Costa,Isaias Raw,Stephen S. Whitehead,Anna P. Durbin,Jorge Kalil +32 more
TL;DR: Butantan-DV and TV003 were both immunogenic, well-tolerated, and no serious adverse reactions were observed, and the primary safety outcome was the frequency of solicited and unsolicited local and systemic adverse reactions within 21 days of the first vaccination.
Journal ArticleDOI
Immunogenicity and Reactogenicity of 2009 Influenza A (H1N1) Inactivated Monovalent Non-Adjuvanted Vaccine in Elderly and Immunocompromised Patients
João Luiz Miraglia,Edson Abdala,Paulo M. Hoff,André Machado Luiz,Danise Senna Oliveira,Carla G. S. Saad,Ieda Maria Magalhães Laurindo,Ana T. R. Viso,Angela Tayra,Lígia Camera Pierrotti,Luiz Sergio Azevedo,Lucia M.A. Campos,Nadia E. Aikawa,Maria do Carmo Sampaio Tavares Timenetsky,Expedito José de Albuquerque Luna,Maria Regina Alves Cardoso,José da S. Guedes,Isaias Raw,Jorge Kalil,Alexander Roberto Precioso +19 more
TL;DR: The H1N1 2009 vaccine was safe among all groups, with an acceptable immunogenicity among the elderly and JIA patients, however new vaccination strategies should be explored to improve the immune response of immunocompromised adult patients.